Logo image of VISTN.OL

VISTIN PHARMA ASA (VISTN.OL) Stock Fundamental Analysis

OSL:VISTN - Euronext Oslo - NO0010734122 - Common Stock - Currency: NOK

24.2  -0.2 (-0.82%)

Fundamental Rating

5

VISTN gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 51 industry peers in the Pharmaceuticals industry. VISTN has an excellent financial health rating, but there are some minor concerns on its profitability. VISTN does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

5

1. Profitability

1.1 Basic Checks

In the past year VISTN was profitable.
In the past year VISTN had a positive cash flow from operations.
In multiple years VISTN reported negative net income over the last 5 years.
The reported operating cash flow has been mixed in the past 5 years: VISTN reported negative operating cash flow in multiple years.
VISTN.OL Yearly Net Income VS EBIT VS OCF VS FCFVISTN.OL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M

1.2 Ratios

VISTN's Return On Assets of 18.66% is amongst the best of the industry. VISTN outperforms 94.12% of its industry peers.
VISTN has a better Return On Equity (23.18%) than 72.55% of its industry peers.
VISTN has a Return On Invested Capital of 21.23%. This is amongst the best in the industry. VISTN outperforms 88.24% of its industry peers.
Industry RankSector Rank
ROA 18.66%
ROE 23.18%
ROIC 21.23%
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
VISTN.OL Yearly ROA, ROE, ROICVISTN.OL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40

1.3 Margins

VISTN has a better Profit Margin (17.44%) than 78.43% of its industry peers.
In the last couple of years the Profit Margin of VISTN has declined.
Looking at the Operating Margin, with a value of 21.55%, VISTN is in line with its industry, outperforming 54.90% of the companies in the same industry.
In the last couple of years the Operating Margin of VISTN has grown nicely.
Looking at the Gross Margin, with a value of 66.70%, VISTN is doing worse than 60.78% of the companies in the same industry.
VISTN's Gross Margin has improved in the last couple of years.
Industry RankSector Rank
OM 21.55%
PM (TTM) 17.44%
GM 66.7%
OM growth 3Y18.14%
OM growth 5Y21.91%
PM growth 3Y17.49%
PM growth 5Y-12.88%
GM growth 3Y-0.06%
GM growth 5Y7.35%
VISTN.OL Yearly Profit, Operating, Gross MarginsVISTN.OL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 60

More info and screens

8

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so VISTN is creating value.
There is no outstanding debt for VISTN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
VISTN.OL Yearly Shares OutstandingVISTN.OL Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M
VISTN.OL Yearly Total Debt VS Total AssetsVISTN.OL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M 400M 500M

2.2 Solvency

An Altman-Z score of 10.76 indicates that VISTN is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 10.76, VISTN belongs to the top of the industry, outperforming 98.04% of the companies in the same industry.
There is no outstanding debt for VISTN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 10.76
ROIC/WACC2.5
WACC8.5%
VISTN.OL Yearly LT Debt VS Equity VS FCFVISTN.OL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M

2.3 Liquidity

VISTN has a Current Ratio of 2.69. This indicates that VISTN is financially healthy and has no problem in meeting its short term obligations.
VISTN has a Current ratio of 2.69. This is amongst the best in the industry. VISTN outperforms 90.20% of its industry peers.
A Quick Ratio of 1.47 indicates that VISTN should not have too much problems paying its short term obligations.
With an excellent Quick ratio value of 1.47, VISTN belongs to the best of the industry, outperforming 80.39% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.69
Quick Ratio 1.47
VISTN.OL Yearly Current Assets VS Current LiabilitesVISTN.OL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M 400M

More info and screens

3

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 36.54% over the past year.
The Earnings Per Share has been decreasing by -1.03% on average over the past years.
Looking at the last year, VISTN shows a small growth in Revenue. The Revenue has grown by 0.44% in the last year.
Measured over the past years, VISTN shows a quite strong growth in Revenue. The Revenue has been growing by 13.56% on average per year.
EPS 1Y (TTM)36.54%
EPS 3Y36.14%
EPS 5Y-1.03%
EPS Q2Q%183.32%
Revenue 1Y (TTM)0.44%
Revenue growth 3Y15.87%
Revenue growth 5Y13.56%
Sales Q2Q%10.74%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
VISTN.OL Yearly Revenue VS EstimatesVISTN.OL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M
VISTN.OL Yearly EPS VS EstimatesVISTN.OL Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 1 2 3

More info and screens

3

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Earnings ratio of 13.99, VISTN is valued correctly.
VISTN's Price/Earnings ratio is a bit cheaper when compared to the industry. VISTN is cheaper than 64.71% of the companies in the same industry.
When comparing the Price/Earnings ratio of VISTN to the average of the S&P500 Index (26.34), we can say VISTN is valued slightly cheaper.
Industry RankSector Rank
PE 13.99
Fwd PE N/A
VISTN.OL Price Earnings VS Forward Price EarningsVISTN.OL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of VISTN indicates a somewhat cheap valuation: VISTN is cheaper than 62.75% of the companies listed in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of VISTN indicates a somewhat cheap valuation: VISTN is cheaper than 74.51% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 13.47
EV/EBITDA 9.37
VISTN.OL Per share dataVISTN.OL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6 8

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

6

5. Dividend

5.1 Amount

With a Yearly Dividend Yield of 5.14%, VISTN is a good candidate for dividend investing.
Compared to an average industry Dividend Yield of 2.92, VISTN pays a better dividend. On top of this VISTN pays more dividend than 90.20% of the companies listed in the same industry.
Compared to an average S&P500 Dividend Yield of 2.40, VISTN pays a better dividend.
Industry RankSector Rank
Dividend Yield 5.14%

5.2 History

Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0

5.3 Sustainability

VISTN pays out 57.73% of its income as dividend. This is a bit on the high side, but may be sustainable.
DP57.73%
EPS Next 2YN/A
EPS Next 3YN/A
VISTN.OL Yearly Income VS Free CF VS DividendVISTN.OL Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M -100M -150M
VISTN.OL Dividend Payout.VISTN.OL Dividend Payout, showing the Payout Ratio.VISTN.OL Dividend Payout.PayoutRetained Earnings

More info and screens

VISTIN PHARMA ASA

OSL:VISTN (6/19/2025, 11:52:06 AM)

24.2

-0.2 (-0.82%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)04-25 2025-04-25
Earnings (Next)08-21 2025-08-21
Inst Owners12.54%
Inst Owner ChangeN/A
Ins Owners4.59%
Ins Owner ChangeN/A
Market Cap1.07B
Analysts40
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 5.14%
Yearly Dividend0
Dividend Growth(5Y)N/A
DP57.73%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 13.99
Fwd PE N/A
P/S 2.44
P/FCF 13.47
P/OCF 10.44
P/B 3.24
P/tB 3.24
EV/EBITDA 9.37
EPS(TTM)1.73
EY7.15%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)1.8
FCFY7.42%
OCF(TTM)2.32
OCFY9.57%
SpS9.93
BVpS7.47
TBVpS7.47
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 18.66%
ROE 23.18%
ROCE 27.23%
ROIC 21.23%
ROICexc 22.03%
ROICexgc 22.03%
OM 21.55%
PM (TTM) 17.44%
GM 66.7%
FCFM 18.09%
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y18.14%
OM growth 5Y21.91%
PM growth 3Y17.49%
PM growth 5Y-12.88%
GM growth 3Y-0.06%
GM growth 5Y7.35%
F-Score7
Asset Turnover1.07
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 120.19%
Cap/Sales 5.25%
Interest Coverage 250
Cash Conversion 90.04%
Profit Quality 103.7%
Current Ratio 2.69
Quick Ratio 1.47
Altman-Z 10.76
F-Score7
WACC8.5%
ROIC/WACC2.5
Cap/Depr(3y)280.38%
Cap/Depr(5y)338.81%
Cap/Sales(3y)11.99%
Cap/Sales(5y)13.71%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)36.54%
EPS 3Y36.14%
EPS 5Y-1.03%
EPS Q2Q%183.32%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)0.44%
Revenue growth 3Y15.87%
Revenue growth 5Y13.56%
Sales Q2Q%10.74%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y27.5%
EBIT growth 3Y36.89%
EBIT growth 5Y38.44%
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y374.74%
FCF growth 3YN/A
FCF growth 5Y158.58%
OCF growth 1Y502.58%
OCF growth 3Y99.03%
OCF growth 5Y41.62%